143 related articles for article (PubMed ID: 23057946)
1. 'Watch and wait' as initial management for patients with follicular lymphomas: still a viable strategy?
Hagemeister FB
BioDrugs; 2012 Dec; 26(6):363-76. PubMed ID: 23057946
[TBL] [Abstract][Full Text] [Related]
2. Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients?
Rueda A; Casanova M; Redondo M; Pérez-Ruiz E; Medina-Pérez A
BMC Cancer; 2012 May; 12():210. PubMed ID: 22650448
[TBL] [Abstract][Full Text] [Related]
3. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
Ardeshna KM; Qian W; Smith P; Braganca N; Lowry L; Patrick P; Warden J; Stevens L; Pocock CF; Miall F; Cunningham D; Davies J; Jack A; Stephens R; Walewski J; Ferhanoglu B; Bradstock K; Linch DC
Lancet Oncol; 2014 Apr; 15(4):424-35. PubMed ID: 24602760
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
5. [Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line].
Castro Gómez AJ; López-Guillermo A; Rueda Domínguez A; Salar A; Varela Moreno C; Rubio-Terrés C
Rev Esp Salud Publica; 2012; 86(2):163-76. PubMed ID: 22991059
[TBL] [Abstract][Full Text] [Related]
6. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.
Vidal L; Gafter-Gvili A; Salles G; Dreyling MH; Ghielmini M; Hsu Schmitz SF; Pettengell R; Witzens-Harig M; Shpilberg O
J Natl Cancer Inst; 2011 Dec; 103(23):1799-806. PubMed ID: 22021664
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
8. Follicular lymphoma: 2011 update on diagnosis and management.
Freedman A
Am J Hematol; 2011 Sep; 86(9):768-75. PubMed ID: 21850659
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?
Kahl B
Hematology Am Soc Hematol Educ Program; 2012; 2012():433-8. PubMed ID: 23233615
[TBL] [Abstract][Full Text] [Related]
10. Has single-agent rituximab replaced watch-and-wait for a patient with asymptomatic low-grade follicular lymphoma?
Lowry L; Ardeshna KM
Cancer J; 2012; 18(5):390-5. PubMed ID: 23006942
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for the treatment of follicular lymphoma.
Cheah CY; Lingaratnam S; Seymour JF
Future Oncol; 2013 Sep; 9(9):1283-98. PubMed ID: 23980675
[TBL] [Abstract][Full Text] [Related]
12. Maintenance rituximab should be considered for patients with follicular lymphoma.
Barr PM
Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
[No Abstract] [Full Text] [Related]
13. Rituximab maintenance therapy in indolent NHL: a clinical review.
Buske C; Hiddemann W
Leuk Res; 2006 Mar; 30 Suppl 1():S11-5. PubMed ID: 16750673
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in indolent lymphomas.
Sousou T; Friedberg J
Semin Hematol; 2010 Apr; 47(2):133-42. PubMed ID: 20350660
[TBL] [Abstract][Full Text] [Related]
15. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
Prica A; Chan K; Cheung M
Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
17. Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.
Reagan PM; Friedberg JW
Curr Treat Options Oncol; 2015 Jul; 16(7):32. PubMed ID: 26031546
[TBL] [Abstract][Full Text] [Related]
18. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
19. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
[TBL] [Abstract][Full Text] [Related]
20. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.
Hainsworth JD; Greco FA; Raefsky EL; Thompson DS; Lunin S; Reeves J; White L; Quinn R; DeBusk LM; Flinn IW
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):277-83. PubMed ID: 24679633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
